CMC Consulting
Total Trials
3
As Lead Sponsor
As Collaborator
0
Total Enrollment
389
NCT04500067
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment
Phase: Phase 3
Role: Lead Sponsor
Start: May 7, 2020
Completion: Sep 15, 2020
NCT05245734
Human Anti-D (rh) Immunoglobulin (Rhesoglobin) Efficacy, Safety and Some Pharmacokinetics Parameters in Pregnant Women
Phase: Phase 4
Start: Feb 8, 2022
Completion: Apr 30, 2025
NCT05422365
Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults
Start: Jul 26, 2022
Completion: Dec 14, 2023
Loading map...